HDAC9 and triple-negative breast carcinoma: Our research demonstrates that metformin, in combination with the HDAC inhibitor SAHA, offers a novel and effective treatment strategy for triple-negative breast cancer (TNBC), showcasing significant advances in targeting this challenging cancer subtype through drug repurposing and mechanistic innovation.